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1. Introduction  
Adenoviruses have been recognized as opportunistic and significant viral pathogens in 
immunocompromised patients such as recipients of hematopoietic stem cells or other solid 
organs treated with immunosuppressive agents, and among patients with acquired 
immunodeficiency syndrome. These patients are incapable of developing a normal immune 
response. Reactivation of adenoviruses in the impaired immunological response leads to 
acute or persistent infections with high morbidity or even mortality in these patients. 
In the field of allogeneic stem cell transplantation in particular, adenovirus infection is one 
of the common complications. A representative consequence of adenovirus infection is 
hemorrhagic cystitis. The cumulative incidence of adenovirus-induced hemorrhagic cystitis 
was found to be 7%, which usually presents a favorable prognosis during the era of bone 
marrow and peripheral blood stem cell transplantation (El-Zimaity et al., 2004, Shields et al., 
1985, Asano et al., 2003). Some cases, however, progress to a retrograde infection of the 
kidneys, and develop to acute renal failure and adenoviremia, resulting in a poor prognosis 
(Bruno et al., 2004). Lion et al. reported that mortality of adenoviremia after stem cell 
transplantation was 91% before the era of cidofovir (Lion et al., 2003).  
In recent years, umbilical cord blood has been increasingly utilized as a source of 
hematopoietic stem cells for transplantation of patients without favorable donors despite its 
immature immune activity which often leads to a prolonged immunological deficiency and 
many kinds of early severe infectious complications such as bacteremia, cytomegalovirus 
disease, tuberculosis and fungal infection (Saavedra et al., 2002, Maeda et al., 2005). The 
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cumulative incidence of adenovirus-induced hemorrhagic cystitis after cord blood 
transplantation was, however, found to be relatively low (2.8%) among Japanese adults 
(Tomonari et al., 2006). It is important that cord blood transplantation is one of the risk 
factors of symptomatic adenoviremia (Robin et al., 2007), which develops to acute renal 
failure in the terminal stage (Abe T et al., 2009).  
At present, there is no established consensus about the treatment for acute renal failure 
induced by adenovirus after stem cell transplantation. This chapter focuses on the recent 
advances in diagnosis, mostly due to the development of molecular methods, and 
therapeutic interventions. Furthermore, this chapter is intended to promote a consensus 
about the methods of early diagnosis and the treatment for this disease. 
2. Serotypes of adenoviruses inducing cystitis and acute renal failure 
The development of more sensitive diagnostic methods enabled us to increase awareness of 
this virus as a pathogen. At least seven human adenovirus species (A to F), including 52 
serotypes, have been described.  
Adenoviruses have mechanisms to escape from host immune responses, such as inhibition 
of interferon functions, inhibition of intrinsic cellular apoptosis in infected cells, and the 
prevention of major histocompatibility complex class I expression on the cell surface (Mahr 
et al., 1999) to reduce cytotoxic T-cell attack of the infected cells (Lichtenstein et al., 2004), 
especially in serotypes 1, 2, and 5 (species C). They persist focally in tonsils for years 
through low-grade replication. Surprisingly, T lymphocytes in tonsils and adenoids may 
harbor adenovirus-DNA (Garnett et al., 2007). This suggests that endogenous reactivation 
may occur during periods of immunosuppression after stem cell transplantation. Persistence 
of adenovirus species C is higher for younger age groups, in which primary infections 
predominantly with species C  occur. The quantity of adenovirus-DNA decreases in an age-
related manner, either from immune elimination or from depletion of latent stores. 
Persistent or latent infection of other species is still unknown.  
Acute renal failure due to adenoviruses is caused by disseminated disease or retrograde 
infection from hemorrhagic cystitis. High persistence of serotype 2 at a young age is 
mentioned in lots of case reports regarding disseminated diseases of this serotype after stem 
cell transplantation. Other prevalent serotypes of disseminated diseases are 31 (species A), 
11, 34, 35 (species B), 1 and 5. On the other hand, prevalent serotypes of hemorrhagic cystitis 
are 7, 11, 34 and 35 (species B) (Echavarría, 2008), especially serotype 11 (Asano et al., 2003). 
The organ tropisms of AdV serotypes remain unclear.  
Multiple serotype infection was found to be more frequent in immunocompromised patients 
(30%) than in immunocompetent patients (5%) (Gray et al., 2007). Our group also experienced 
sequential adenovirus infection of serotype 14 hemorrhagic cystitis and serotype 35 
disseminated infection after cord blood transplantation (Abe T et al., 2009). Serotype 14 is a 
group B adenovirus, which is associated with pharyngo-conjunctival fever (Tuck et al., 1957). 
This infection was infrequently reported as an acute respiratory disease in military recruits 
(Van der Veen & Kok, 1957, Hierholzer & Pumarola, 1976, Metzgar et al., 2007), and recently 
caused pediatric lower airway disease in Taiwan during 2001-2002 (Chen et al., 2002). A new 
variant of this serotype also caused life-threatening pneumonia in the United States (Louie et 
al., 2008). Serotype 35 has been detected in urine of patients with acquired immunodeficiency 
syndrome (AIDS) and other immunodeficiencies (de Jong et al., 1983, Shields et al., 1985, 
Stalder et al., 1977). Furthermore, an outbreak of serotype 35 pneumonia among residents and 
staff of a psychiatric facility was reported (Sanchez et al., 1997). 
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3. Pathological findings and methods of diagnosis 
3.1 Pathological findings of acute renal failure induced by adenovirus  
Hemorrhagic, necrotizing tubulitis with intranuclear inclusion bodies is observed in autopsy 
of patients with acute renal failure induced by adenoviruses after stem cell transplantation 
or intensive chemotherapy for acute leukemia. 
 
 
Fig. 1. Necrosis with interstitial hemorrhage of the kidneys of our autopsied patient.  
(hematoxylin–eosin stain, magnification x20)  
Interstitial hemorrhage is specific to adenovirus (Figure 1) and is different from other viral 
nephritis after stem cell transplantation such as those with BK virus or cytomegalovirus 
(Colvin, & Nickeleit, 2007). Histopathologically, necrobiotic tubular cells are classified into 
inclusion-bearing cells of three types: 1) "smudge cells," 2) "Cowdry A" intranuclear inclusion 
cells including intranuclear eosinophilic amorphous or droplet-like bodies surrounded by a 
homogeneous clear halo, with marginations of chromatin on the nuclear membrane, and 3) 
"full-type" intranuclear-containing cells (Cowdry, 1934, Ito et al., 1991)(Figure 2).  
Yuzawa et al. showed that these granular deposits contain adenovirus related antigens, 
immunoglobulins, and C3, which suggests that granular deposits may be formed "in situ" by 
viral antigens and circulating viral antibodies (Yuzawa et al., 1993).  
It is definitive that immunofluorescent examination with anti-adenovirus antibody 
demonstrates specific fluorescence on the affected tubular cells (Figure 3).  
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Fig. 2. The three types of inclusion bodies: Cowdry A(long arrow), full-type (intermediate-
length arrow) and smudge-type (short arrow) are identified in the affected tubules 
(hematoxylin–eosin stain, magnification x40).  
 
 
Fig. 3. Adenovirus antigens in affected tubular cells of our autopsied patient are revealed by 
immunofluorescent examination (magnification x100). Serotype-specific antigen can also be 
revealed by this method. 
Electron microscopy can reveal intranuclear crystalline arrays of viral particles, 75 to 80 nm in 
diameter (Ito et al., 1991, Mori et al., 2003), but it is not routinely used in clinical laboratories. 
3.2 Methods of diagnosis for acute renal failure induced by adenovirus 
3.2.1 Clinical manifestations of acute renal failure induced by adenovirus 
Adenovirus is usually detected in the recipients of stem cell transplantation within 100 
posttransplant days. The mean time is 58 days, ranging from -44 to 333 days (Ljungman et 
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al., 2003). Adenovirus causes acute renal failure, which follows adenovirus-induced 
hemorrhagic cystitis or adenoviremia. At first, in hemorrhagic cystitis cases, the risk factors 
include acute graft versus host disease of more than grade II, male, old age, allogeneic stem 
cell transplantation and the use of busulfan in a conditioning regimen (Asano et al., 2003, 
Sencer et al., 1993, Seber et al., 1999, Leung et al., 2002). Common clinical symptoms are 
gross hematuria and lower abdominal pain. Some cases lead to hydronephrosis and acute 
post-renal failure due to obstruction of the terminal ureters by edematous change of the 
ureterovesical junction (Figure 4). 
 
 
Fig. 4. Hydronephrosis and acute post-renal failure in our patient due to obstruction of the 
terminal ureters by edematous change of the ureterovesical junction after the onset of  
adenovirus-induced hemorrhagic cystitis. 
Back or flank pain is a critical symptom that indicates a retrograde infection to kidneys, risk 
factor for which is graft versus host disease. Furthermore, adenovirus-induced nephritis is a 
high risk factor for disseminated adenovirus infection including symptomatic adenoviremia 
(Bruno et al., 2004). Clinical presentation of adenoviremia is low to high grade fever 
refractory to antibiotic or antifungal agents followed by multiple organ failure including 
acute renal failure which presents oliguria, elevation of serum creatinine and enlarged 
kidneys with hypo-density in CT scan. Risk factors of disseminated adenovirus infection 
including symptomatic adenoviremia are graft versus host disease, and, T-cell-depleted 
graft and cord blood transplantation (Robin et al., 2007, Kampemann et al., 2005). On the 
other hand, asymptomatic infections with detection of adenovirus from blood or urine have 
been observed (Lion et al., 2003). 
3.2.2 Methods of molecular diagnosis for acute renal failure induced by adenovirus  
Adenovirus-DNA has been detected in almost all clinical samples. In adenovirus-induced 
hemorrhagic cystitis cases before acute renal failure, the most rapid and handy qualitative 
diagnosis kit is immunochromatography, for example, adenocheck (Santen, Osaka, Japan, or 
SA Scientific, Texas, U.S.) (Nagafuji et al., 2004). This kit enables us to detect more than 1x104 
viral particles /ml in urine at the bedside, although it was developed for the diagnosis of 
adenovirus conjunctivitis.   
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Polymerase chain reaction (PCR) has been used as a rapid and very useful method, and is 
the most prevalent assay for the diagnosis of adenovirus infection. The clinical specificity of 
the PCR for urine was found to be 96% (Echavarría et al., 1998). To diagnose symptomatic 
adenovirus infection such as hemorrhagic cystitis, adenoviremia or acute renal failure, at 
first, DNA is extracted from the patient’s urine, blood or renal biopsy sample. When acute 
renal failure and adenoviremia occur simultaneously, the patient may be diagnosed with 
adenovirus-induced acute renal failure without renal biopsy. Then nested PCR is performed 
to amplify the RNA gene, hexon gene or fiber gene of adenovirus with more than one pair 
of primers in a thermal cycler as shown in Figure 5. (Saito-Inagawa et al., 1996, Shimada et 
al., 2004, Lu & Erdomann, 2006, Leruez-Ville et al., 2004, Lion et al., 2003).  
 
 
 
 
 
 
    
 
 
 
Fig. 5. Quantitative PCR using DNA extracts from the patient’s samples is performed with a 
pair of primers, for example, as shown in the paper of Lion et al., and with a pair of TaqMan 
probes for quantification, for example, 5‘-(FAM)-CCCATGGATGAGCCCACCCT-
(TAMRA)-3‘ and 5‘-(FAM)-CCCATGGACGAGCCCACCCT-(TAMRA)-3‘, in a thermal 
cycler. The thermal conditions were 50°C for 2 min, 95°C for 10 min, then 50 cycles at 95°C 
for 15 sec and 60°C for 1 min. Amplification standard was made for each number of control 
DNA copies from 101 to 107, which enabled us to quantify the number of viral DNA copies 
from the patient’s samples. 
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Fig. 6. The nucleotide sequences of amplified fragments were determined with a DNA auto 
sequencer with fluorescent dideoxy chain terminators. For example, the sequences of the 
amplified adenovirus-DNA from our autopsied patients (at the first line) were analyzed and 
compared with the 51 prototype strains in the GenBank database (below the next line), and 
finally the serotype was identified as 35. 
This method is real-time PCR, which can be a qualitative or quantitative assay since 
amplification and detection of amplified products occur simultaneously. Then, typing is 
performed. Typing is primarily used for epidemiologic investigations, for studies on 
pathogenesis such as multiple serotype infections, for unusual or especially severe 
infections, or for treatment approaches such as high titer γ-globulin. The nucleotide 
sequences from these fragments were determined by a DNA auto sequencer with 
fluorescent dideoxy chain terminators. The sequences of the amplified adenovirus-DNA 
were analyzed and compared with the 51 prototype strains in the GenBank database, and 
finally the serotypes were identified (Figure 6)(Abe T et al., 2009). This method with 
sequencing is increasingly performed because it is rapid and now available in many 
laboratories with molecular equipment, and does not require expensive or difficult-to-obtain 
antisera. However, there is no clear viral load cut-off value that predicts disease outcome. 
Thus, it may be preferable to analyze the viral kinetics for each patient, considering the 
adenoviral load over time rather than the absolute value among symptomatic patients 
(Leruez-Ville et al., 2004).  
PCR is highly sensitive and especially applicable for asymptomatic adenovirus infection 
surveillance of blood samples, perhaps weekly, and at present, it is commonly applied in 
stem cell recipients. The virus can be detected in blood 2 to 3 weeks before development of 
clinical symptoms, which offers the opportunity for intervention (Lion et al., 2003) to avoid 
acute renal failure and hemodialysis. 
4. Treatment to avoid hemodialysis before and during hemorrhagic cystitis  
Conventional treatments of hemorrhagic cystitis are hyper-hydration, diuresis and bladder 
irrigation to wash out viral particles and clots, and to prevent retrograde infection to 
kidneys and post-renal failure due to urethral obstruction caused by clots. High titer γ-
globulin to specific adenovirus serotype is also administrated. In particular, serotype 35 
specific antibody was present only at a very low titer in pooled gamma globulin 
(Flomenberg et al., 1987). Our group experienced sequential different serotype adenovirus 
infection of serotype 14 hemorrhagic cystitis and serotype 35 disseminated infection after 
cord blood transplantation, which is too confusing to treat because of the contrast between 
the improvement of adenovirus-induced hemorrhagic cystitis by serotype 14 high titer γ-
globulin and the progression of acute renal failure (Abe T et al., 2009). 
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At present, Ribavirin and Cidofovir are antiviral agents used in the treatment of adenovirus. 
More evidence has been obtained for the efficacy of Cidofovir. Recent reports showed that 
69-98% of patients with adenovirus disease were successfully treated with Cidofovir (Yusuf 
et al., 2006, Ljungman, 2003). Nagafuji et al. reported that 71% of patients with adenovirus-
induced hemorrhagic cystitis were successfully treated with Cidofovir (Nagafuji et al., 2004). 
Therefore, Cidofovir is recommended as the first line treatment for adenovirus-induced 
hemorrhagic cystitis. Cidofovir is a monophosphate nucleotide analog of cytosine that can 
inhibit viral DNA polymerase and viral replication. 
For a preemptive therapy before the onset of adenovirus-induced hemorrhagic cystitis, 
Ljungman et al. showed tthat, for 13 (81%) of 16 patients, asymptomatic infection was resolved 
when Cidofovir was given as a preemptive therapy (Ljungman et al., 2003). Lindemans et al. 
presented a practical guidelines for the treatment of adenovirus infections in recipients of stem 
cell transplantation by using Cidofovir including a preemptive therapy (Lindemans et al., 
2010). The guidelines take three risk factors into consideration: cord blood transplantation, T-
cell-depleted graft, and immune-suppression, and divide the patients into low-, intermediate-, 
and high-risk groups, each with a different treatment approach depending on the viral load 
measured by weekly or twice weekly peripheral blood quantitative PCR. The presence of these 
risk factors determines individual susceptibility to the development of adenovirus disease in 
the case of reactivation. At first, the low-risk group includes cases other than cord blood 
transplantation or T-cell-depleted graft, or at more than 4 months after stem cell 
transplantation for any donor source with immune-suppression by a lymphocyte proliferation 
inhibitor such as calcineurin inhibitor and/or less than0.5 mg/kg predonisolone. Furthermore, 
low risk group is divided into two groups by CD3 positive T cell count in peripheral blood. 
When adenovirus is detected in peripheral blood more than 100 copies/ml, absence of T cells 
(CD3+< 25/µL) or the immunoresponse failure to adenovirus shortly after adenovirus 
detection (CD3+ T cells < 300/µL within 2 weeks of adenovirus detection) leads to the same 
treatment of intermediate risk group because it has been associated with a poor outcome. The 
number of CD3-positive T cells has been shown to be critical in the development of infectious 
disease in the case of viral reactivation, and in the ultimate clearance of the virus (Chakrabarti 
et al., 2002, Heemskerk et al., 2005). The intermediate-risk group includes cases of cord blood 
transplantation or T-cell-depleted graft 1 to 4 months after stem cell transplantation with 
immune-suppression by more than two lymphocyte proliferation inhibitors (e.g., cyclosporine-
A and mycophenolate mofetil) or a lymphocyte proliferation inhibitor and 0.5-1 mg/kg 
prednisolone. The high-risk group includes cases of cord blood transplantation or T-cell-
depleted graft within a month after stem cell transplantation, and immune-suppression by 
more than one lymphocyte proliferation inhibitor and more than 1 mg/kg prednisolone. 
Critical viral load in peripheral blood for pre-emptive treatment is more than 10,000 copies in 
low-, more than 1,000 copies in intermediate-, and more than 100 copies in high-risk groups, 
respectively. Symptomatic adenovirus diseases are also critical for treatment. The treatment 
regimen for Cidofovir is 1 mg/kg per day three times weekly until viral load decreases to less 
than 400 copies/ml for more than two weeks and CD3+ T cells increase to more than 300/µl 
(Kampmann et al., 2005, Chakrabarti et al., 2002). If possible, immunosuppressive drugs 
should be tapered (Kampmann et al., 2005, Chakrabarti et al., 2002). Because of the marked 
nephrotoxicity of Cidofovir, hyperhydration together with oral Probenecid (2 g) given 3 h 
before Cidofovir administration is essential for nephroprotection (Nagafuji et al., 2004, 
Anderson et al., 2008, Hoffman et al., 2001). Viral load increases of more than 1 log /week or 
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patient presentation of adenovirus disease symptoms is indicative of therapy failure and 
immunotherapy (described later) should be considered.  
There is weak evidence for the efficacy of Ribavirin against adenovirus, and its in vitro anti- 
adenovirus activity differs widely against different serotypes (most active against group C, 
subtype 1, 2, or 5) (Morfin et al., 2005). There are several case reports suggesting therapeutic 
benefit for some patients (Homma et al., 2008, Abe S et al., 2003, Lankester et al., 2004). 
Recently, a strategy combining prophylactic Ribavirin and preemptive Cidofovir treatment 
was described (Greil et al., 2006). Comparing the outcome with Historical controls in which 
no prophylaxis and Cidofovir alone was given as a preemptive treatment, the combined 
strategy with Ribavirin prophylaxis resulted in a significantly lower incidences of 
adenovirus infection (29% vs 66%) and adenovirus-associated mortality (0% vs 14%).  
Although prophylaxis or preemptive therapy shows favorable effects on adenovirus 
infection, even Cidofovir has only limited efficacy when started as therapeutic treatment for 
disseminated adenovirus diseases in intermediate- and high-risk groups (Robin et al., 2007, 
Symeonidis et al., 2007). It is important that early detection of Adenoviremia enables us to 
initiate therapy before a significant increase in mortality (La Rosa et al., 2001).  
Although less efficient than Cidofovir or Ribavirin, Ganciclovir can interfere with the 
function of adenovirus DNA polymerase, thus inhibiting viral replication in vitro (Lenaerts 
et al., 2008). In retrospective studies, lower incidences of adenovirus infections appeared to 
be reported in patients treated with Ganciclovir as cytomegalovirus prophylaxis (Bruno et 
al., 2003). Reports of a positive outcome in patients with adenovirus infection treated with 
Ganciclovir are uncommon (Chen et al., 1997). In some countries like Japan, Cidofovir is not 
available. Ganciclovir may be useful in these countries until Cidofovir becomes available. 
Vidarabine is also active in vitro against adenovirus (Kurosaki et al., 2004). There have been 
a few case reports of successful vidarabine therapy of adenovirus hemorrhagic cystitis. 
Bordigoni et al. reported results obtained in seven recipients of stem cell transplantation 
treated with vidarabine, but none survived (Bordigoni et al., 2001). 
5. Treatment for acute renal failure induced by adenovirus   
Adenovirus causes acute renal failure through hemorrhagic cystitis or as a symptom of 
disseminated disease. In this phase, treatment options are severely limited. If possible, 
tapering or termination of immunosuppressive agents is indicated to prompt immune 
reaction against adenovirus, although the risk of graft versus host disease progression may 
increase. Of course, oliguria is an indication of hemodialysis. When post-renal failure with 
hydronephrosis is caused by clots or swelling of the ureterovesical junction in patients with 
adenovirus-induced hemorrhagic cystitis, percutaneous nephrostomy may be indicated 
(Mori et al., 2003). Regarding the administration of antiviral agents in severe renal 
dysfunction, serum elimination half-time of Cidofovir increases so significantly that its 
nephrotoxicity may force the patients into hemodialysis. Therefore, drug clearance should 
be carefully considered. Brody et al. showed that mean +/- SD of Cidofovir clearance in 
patients with renal dysfunction was 0.94 x cleatinine clearance (mL/min/kg) + 0.064 
mL/min/kg while its clearance in normal control was 1.7 +/- 0.1 mL/min/kg (Brody et al., 
1999). Ribavirin is contraindicated for patients with renal failure whose creatinine clearance 
is less than 50 ml/min. During the period of hemodialysis, high-flux hemodialysis resulted 
in the removal of 52% +/- 11% of Cidofovir administered (Brody et al., 1999). Ribavirin, 
however cannot be removed by hemodialysis (Kramer et al., 1990). In a case report, 
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reduction of immunosuppression and one dose of Cidofovir (2 mg/kg) were effective for 
adenovirus-induced acute renal failure on hemodialysis, and showed resolution of viremia 
and viruria and return of renal function to near baseline without coadministration of 
Probenecid to ensure adequate drug delivery to the proximal tubular cells (Sujeet et al., 
2010). Nevertheless, treatment failure with Cidofovir indicates immunotherapy such as 
donor lymphocytes or adenovirus-specific cytotoxic T cells in the initial therapy of 
adenovirus-induced hemorrhagic cystitis or acute renal failure, and in the preemptive 
therapy according to the guidelines descrived above.  
Donor lymphocyte infusion in allogeneic stem cell transplantation is an adoptive T cell transfer 
protocol based on the hypothesis that donor peripheral blood containing T cells can mediate 
antiviral activity. Hromas et al. reported a case of a 19-year-old man who underwent a T-cell-
depleted allogeneic stem cell transplantation for T-cell lymphoblastic lymphoma. After 
treatment failure with antiviral drugs for adenovirus-induced hemorrhagic cystitis, he was 
given donor leukocytes (1 x 106 CD3 cells/kg) and subsequently cleared the virus (Hromas et 
al., 1994). A number of other case studies followed with similar positive outcomes 
(Chakrabarti et al., 2002, Howard et al., 1999, Bordigoni et al., 2001, Chakrabarti et al., 2000). 
Patients were infused with cell doses ranging from 1 x 105 to 3 x 107 CD3 cells/kg. Donor 
lymphocyte infusion is, however, impossible in patients after cord blood transplantation and 
often regarded as the last choice of the treatment option because the efficacy of this approach is 
limited by the low frequency of T cells specific to adenovirus and the relatively high frequency 
of graft versus host disease caused by alloreactive T cells. Graft versus host disease itself is a 
risk factor of disseminated adenovirus diseases because the therapy for graft versus host 
disease requires steroids, which suppress adenovirus-specific T cells. To reduce the risk of 
donor lymphocyte infusion, inactivation or selective removal ex vivo of alloreactive T cells, or 
suicide gene transfer has been investigated (Davies et al., 2008, Comoli et al., 2008, Andre-
Schmutz et al., 2002, Solomon et al., 2002, Amrolia et al., 2003, Montagna et al., 1999, Ciceri et 
al., 2009, Tey et al., 2007).  
To improve the safety and efficacy of the adoptive transfer approach to donor lymphocyte 
infusion, adenovirus-specific T cell selection from donor peripheral blood and expansion in 
vitro have been investigated. Feuchtinger et al. directly identified and isolated donor 
peripheral blood T cells that secreted IFN-γ in response to stimulation with adenovirus 
antigen, and expanded the cells with the stimulation of adenovirus lysate in vitro. Then the 
isolated T cells were transferred into 9 pediatric recipients of allogeneic stem cell 
transplantation with systemic adenovirus infection despite conventional therapy. The 
frequency of adenovirus-specific T cells in donor peripheral blood increased from 1.1% +/- 
1% to 45.7% +/- 24% after selection. None of the infusions (range, 1,200-50,000 CD3+ 
cells/kg) was associated with toxicity in vivo, and 5 of 6 evaluable patients showed a 
significant decrease of adenoviral DNA in peripheral blood and stool with a corresponding 
increase in the frequency of adenovirus-specific T cells in vivo (Feuchtinger et al., 2006). 
Leen et al. has achieved similar success in adoptive immunotherapy by using in vitro–
expanded adenovirus, EB virus, and cytomegalovirus-specific cytolytic T-cell (CTL) lines 
(Leen et al., 2006). For the production of the trivirus CTL lines, EB virus-transformed 
lymphoblastoid cell lines were used as antigen-presenting cells, which also presented EB 
virus antigens, and adenovirus vectors into which a cytomegalovirus antigen was 
introduced were transduced with these antigen-presenting cells. Cells were infused as a 
prophylaxis from day 30 after transplantation in recipients of HLA- haploidentical stem cell 
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transplantation as well as HLA-matched related, and matched unrelated cases within grade 
II acute graft versus host disease. The infused doses ranged from 1.7 x 105 to 4.5 x 106 cells / 
kg, and could control ongoing drug-resistant virus infections. No toxicity or acute graft 
versus host disease was observed. Adenovirus-specific T cells increased only in patients 
with recent or concurrent adenovirus infection, although the reactive T cells against the 
latent EB virus and cytomegalovirus routinely increased independently of detectable viral 
reactivation. None of the treated patients developed a de novo adenovirus infection for at 
least 8 weeks. All patients with detectable adenovirus in blood, stool, or tracheal aspirate (7 
of 24) had a marked reduction in adenoviral load coincident with the rise in their 
adenovirus-specific T cells irrespective of infection serotype, including one patient who 
recovered from progressive adenoviral pneumonia requiring ventilatory support. Although 
adenovirus-specific CTL may be a safe and effective therapy, there are some serious 
problems such as high cost, preparation of large blood volume, and a prolonged period for 
the manufacturing process with special technical skill for 10-12 weeks. Therefore, the 
indication of this therapy should be limited in cases resistant to antiviral agents, but the 
preparation of this therapy should be started as early as possible.  
6. Future perspectives (conclusion) 
In the future, preemptive therapy for adenovirus will be established, and CTL therapies will 
be more standardized, rapid, cost-effective and available in all institutes. Other methods 
such as boosting immune recovery, dendritic therapy and new antiviral drugs are now also 
being developed. These new methods will enable resolution of the severe limitations in the 
treatment of adenovirus-induced acute renal failure. 
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